Strong optomap uptake drives Optos' top-line
This article was originally published in Clinica
Scottish ophthalmic equipment developer Optos has succeeded in narrowing its full-year losses by 58% to $1.1m, as well as driving its revenues up 40% to $67.7m for fiscal 2006. The firm also improved its cash flow from operating activities by 59% to $26.7m, due to the increased scale and operating profitability of the business.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.